Be The Match BioTherapies

Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program (NMDP)/Be The Match, we have unparalleled experience managing cellular therapies. Our cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a technology platform, MatchSource®. Our experience in cell sourcing and collection allows us to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through our research program CIBMTR. And, we have the infrastructure in place to collect, store and analyze patient samples post-cell or gene therapy treatment at the time points required by regulatory authorities.

6 Considerations When Evaluating Cell Sourcing Vendors

Including questions to ask potential cell sourcing partners

Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

Being an NMDP/Be The Match courier during COVID-19

Making essential treatments possible in the midst of a pandemic

How CAR-T reimbursement discussions help advance the field

Proposed IPPS rule an encouraging step towards a clearer payment process

Be The Match BioTherapies CEO’s path to biotech

How a personal experience led her on a mission to save lives through cellular therapy

5 Qualities to Seek in Your Cell Therapy Supply Chain Vendor

Considerations to help lower your cell or gene therapy logistics risk

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

Can cell therapies unlock the COVID-19 mystery?

The promise of MSC therapies to treat deadly manifestations of cytokine storms

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity